v2.4.1.9
Fair Value Measurements - Additional Information (Detail) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Jun. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2014
CommercialTests
Jun. 30, 2014
Apr. 17, 2014
Jul. 31, 2014
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]                
Transfers between Level 1, Level 2 and Level 3 categories during the periods   $ 0cdna_FairValueMeasurementsInterTransfersBetweenLevels            
Estimated fair value of embedded derivative liabilities 239,000us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet         239,000us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet    
Fair value of derivative 120,000us-gaap_DerivativeFairValueOfDerivativeNet         120,000us-gaap_DerivativeFairValueOfDerivativeNet    
Gain on derivative 119,000us-gaap_DerivativeGainLossOnDerivativeNet (118,000)us-gaap_DerivativeGainLossOnDerivativeNet 0us-gaap_DerivativeGainLossOnDerivativeNet 0us-gaap_DerivativeGainLossOnDerivativeNet        
Illumina, Inc. [Member]                
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]                
Subordinated convertible promissory note issued             5,000,000us-gaap_ConvertibleSubordinatedDebt
/ dei_LegalEntityAxis
= cdna_IlluminaIncMember
 
ImmuMetrix, Inc. [Member]                
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]                
Number of commercial tests involving the measurement of cfDNA to be completed   2,500cdna_NumberOfCommercialTests
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
    2,500cdna_NumberOfCommercialTests
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
     
Milestone description   The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.            
Contingent consideration maturity date   Jun. 10, 2020            
IPO [Member]                
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]                
Change in control for repayment           5.00%cdna_ChangeInControlForRepayment
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_IPOMember
10.00%cdna_ChangeInControlForRepayment
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_IPOMember
 
Fair value of derivative               0us-gaap_DerivativeFairValueOfDerivativeNet
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_IPOMember
Gain on derivative               $ 120,000us-gaap_DerivativeGainLossOnDerivativeNet
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_IPOMember
Contingent consideration [Member] | ImmuMetrix, Inc. [Member]                
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]                
Contingent obligation to issue common stock         227,845us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember
     
Milestone description   The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.            
Probability of the achievement         65.00%cdna_FairValueInputProbabilityOfAchievement
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember